Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. (NASDAQ:JANX) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Janux Therapeutics, Inc. (NASDAQ:JANX) has a consensus rating of buy or equivalent from the majority of the analysts covering the stock. The gap between the high and consensus low price targets is also wide: the consensus 1-year median price target implies nearly 249% upside, while the high price target implies around 948% upside, and the lowest price target implies a 75% upside.

On December 17, Barclays trimmed the price target on Janux Therapeutics, Inc. (NASDAQ:JANX) to $29 from $48, with an unchanged ‘Overweight’ rating. This revision, implying an upside potential of about 103%, is part of the firm’s 2026 outlook.

Later, on December 23, Janux Therapeutics, Inc. (NASDAQ:JANX) provided an update on its Phase 1 study of JANX008, its EGFR-targeted TRACTr. The study evaluates “safety, pharmacokinetics/pharmacodynamics, and evidence of clinical activity.” JANX008 is targeted at the epidermal growth factor receptor (EGFR) and is being evaluated for the treatment of multiple solid tumors, including colorectal carcinoma, non-small cell lung cancer, and small cell lung cancer.

According to the press release,

“The Phase 1a dose-escalation portion of the study has been completed, and the program has initiated expansion cohorts to enable further evaluation and support continued dose optimization across selected solid tumor settings.”

Janux Therapeutics, Inc. (NASDAQ:JANX) is a California-based clinical-stage biopharmaceutical company developing immunotherapies based on the TRACTr and TRACIr platform technologies. Founded in 2017, the company focuses on treating patients with cancer.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.